Thanh Hoa Medical Materials Pharmaceutical Joint Stock Co
UUPCOM:DTH14,000.00
VND
-2,000.00
(-12.50%)
ISIN
VN000000DTH3
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
2.94
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Thanh Hoa Vietnam
- IPO Date
- Apr 18, 2022
- Website
- thephaco.vn
- Similar Companies
- Business
- Thanh Hoa Medical Materials Pharmaceutical Joint Stock Company (THEPHACO) is a Vietnam-based pharmaceutical enterprise engaged in the development, manufacture, processing, import-export, and distribution of pharmaceutical products, traditional herbal medicines, health supplements, and medical supplies. The company's core product offerings comprise Western pharmaceuticals, including penicillins, non-beta-lactam antibiotics, anti-infectives, analgesics, antipyretics, anti-inflammatory agents, cardiovascular drugs, diuretics, respiratory medications, gastrointestinal remedies, and dermatological and ENT formulations; traditional and oriental herbal medicines, including proprietary botanical treatments such as Hydan and anti-rheumatic formulas; health and dietary supplements, featuring its Biofil oral tonic line, multivitamin complexes, and soft gel nutritional supplements; and medical materials, including surgical consumables, disposable healthcare supplies, diagnostic devices, and medical apparatus. THEPHACO operates WHO-GMP-certified manufacturing facilities in Thanh Hoa Province dedicated to modern medicines and oriental herbal pharmaceuticals, alongside HS-GMP-compliant lines supporting high-capacity automated soft capsule output exceeding 240 million units per year. The company markets and distributes its product portfolio to hospitals, healthcare centers, commercial pharmacies, and retail consumers across Vietnam through a nationwide supply network of nearly 30 regional branches and more than 50 retail centers, while supplying export trading partners in Asia. Founded in April 1961 and headquartered in Thanh Hoa City, Vietnam, the company underwent equitization in 2002 and completed privatization in 2015. In recent developments, THEPHACO has pursued strategic manufacturing modernization roadmaps to upgrade facilities toward EU-GMP benchmarks, expanded soft capsule processing infrastructure, broadened its institutional drug-supply contract wins in centralized municipal and provincial hospital procurement tenders, and sustained consistent annual cash dividend payouts to shareholders.